Equation | Independent variable | Dependent variable | B | SE | P | OR(95%CI) | Za × Zb | Asymmetric 95% CIZa×Zb | Mediating effect (%) |
---|---|---|---|---|---|---|---|---|---|
Model 1* | |||||||||
  1)c | UA (every increased 10 μmol/L) | Mildly decreased eGFR | 0.054 | 0.014 | < 0.001 | 1.055 (1.028–1.084) | 16.037 | 0.015–0.079 | 25.0 |
  2)a | UA (every increased 10 μmol/L) | Increased 24 h-MAU | 0.045 | 0.009 | < 0.001 | 1.046 (1.028–1.064) |  |  |  |
  3)b | Increased 24 h-MAU | Mildly decreased eGFR | 0.959 | 0.299 | 0.001 | 2.609 (1.453–4.683) |  |  |  |
  c’ | UA (every increased 10 μmol/L) |  | 0.040 | 0.014 | 0.005 | 1.041 (1.012–1.070) |  |  |  |
Model 2* | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  1)c | Hyperuricemia | Mildly decreased eGFR | 0.865 | 0.278 | 0.002 | 2.374 (1.376–4.095) | 14.115 | 0.170–1.162 | 20.1 |
  2)a | Hyperuricemia | Increased 24 h-MAU | 0.693 | 0.172 | < 0.001 | 2.000 (1.427–2.803) |  |  |  |
  3)b | Increased 24 h-MAU | Mildly decreased eGFR | 1.030 | 0.294 | < 0.001 | 2.800 (1.574–4.980) |  |  |  |
  c’ | Hyperuricemia |  | 0.691 | 0.294 | 0.019 | 1.996 (1.121–3.552) |  |  |  |